Dextrose 50% Injection Prefilled Syringes Luer-Jet Luer-Lock 50 mL, 10/pack (Rx)

Immediate Treatment for Hypoglycemia and Emergency Blood Sugar Restoration

Dextrose 50% Prefilled Syringe by International Medication Systems is the gold-standard, ready-to-use hypertonic glucose solution trusted by hospitals, EMS, emergency rooms, and critical care teams. Each 50 mL Luer-Jet Luer-Lock syringe delivers an exact 25 grams of D50W for rapid IV administration—crucial for life-threatening hypoglycemia, insulin shock, or as an emergency carbohydrate source in altered mental status. Pharmaceutically precise, sterile, and preservative-free, this D50 syringe is essential for any crash cart, code blue kit, or ambulance.

Uses

Dextrose 50% Prefilled Syringes are indicated for:

• Immediate treatment of severe hypoglycemia (low blood sugar) in adults and older children
• Altered mental status of unknown diabetic cause—to rule out/treat hypoglycemia in unconscious, seizing, or non-responsive patients
• Insulin shock or diabetic emergencies
• Emergency carb source for perioperative, trauma, or ICU patients unable to take oral/enteral glucose
• Adjunctive therapy in some hyperkalemia protocols (administered with insulin to stabilize serum potassium)
• Part of code blue, EMS, and advanced life support (ALS/ACLS) kits

Order Dextrose 50% Prefilled Syringes (D50W Syringe) – Fastest Solution for Emergency Hypoglycemia Rescue

Equip your crash carts, ambulances, and emergency rooms with the gold-standard IV glucose solution trusted by professionals for effective hypoglycemia reversal—D50W Prefilled Syringe by International Medication Systems.

NDC: 76329-3302-01 | UPC: 376329330211 Prescription required. Professional and institutional use only.

Uses and Applications

Dextrose 50% Prefilled Syringes are indicated for:

• Immediate treatment of severe hypoglycemia (low blood sugar) in adults and older children
• Altered mental status of unknown diabetic cause—to rule out/treat hypoglycemia in unconscious, seizing, or non-responsive patients
• Insulin shock or diabetic emergencies
• Emergency carb source for perioperative, trauma, or ICU patients unable to take oral/enteral glucose
• Adjunctive therapy in some hyperkalemia protocols (administered with insulin to stabilize serum potassium)
• Part of code blue, EMS, and advanced life support (ALS/ACLS) kits

Not for routine nutrition; exclusively for acute IV use in emergencies.

Product Specifications

• Active Ingredient: Dextrose, USP, 50 grams per 100 mL (supplied as 50 mL = 25 grams of dextrose)
• Formulation: Clear, colorless, sterile, preservative-free hypertonic solution
• Concentration: 50% w/v (500 mg/mL)
• Volume: 50 mL per prefilled Luer-Jet Luer-Lock syringe
• Syringe Type: Single-use, ready-to-inject, Luer-Lock tip for compatible IV/IO connection; needle not included
• Packaging: Individually wrapped; box count per distributor
• Manufacturer: International Medication Systems
• NDC: 76329-3302-01
• UPC: 376329330211
• Latex-free, pharmacy grade
• Storage: Room temperature (68–77°F/20–25°C); protect from freezing

How to Use

1. Confirm diagnosis of hypoglycemia with bedside glucose testing if time allows.
2. Inspect syringe for clarity and integrity.
3. Remove from packaging, attach to a Luer-Lock-compatible IV line, IV catheter, or IO device.
4. Administer the full syringe as a slow IV push (preferably via a large, patent vein). Rapid administration is often warranted in critical hypoglycemia.
5. Monitor for phlebitis/infiltration. Flush line post-dose.
6. Recheck blood glucose 5–10 minutes after administration and continue monitoring per protocol.
7. If no response, consider repeating or alternative management based on blood glucose levels and clinical response.

FOR PROFESSIONAL USE ONLY.

Dosage and Administration

Adults (Emergency Hypoglycemia):

• Typical dose: 25 grams = 50 mL of D50W IV push
• Repeat as needed after reassessment (total dose varies based on response and cause)

Pediatrics and Infants:

• D10W or D25W preferred; D50W usually diluted to avoid vein damage
  • Recommended pediatric dosing: 0.2–0.5 g/kg IV (0.4–1 mL/kg D50W; typically diluted 1:1 with sterile water or saline)
• Do not administer undiluted D50W to neonates/infants

Follow institutional protocols for maximum single dose and repetition interval. High concentrations can cause local tissue injury if extravasated—monitor closely.

Drug Interactions

• Insulin and oral hypoglycemics: Pharmacological antagonism (correction of hypoglycemia)
• Potassium-lowering protocols: Administered with insulin in hyperkalemia to prevent hypoglycemia
• Thiazide diuretics, corticosteroids: May cause additional hyperglycemia
• Monitor for interactions in polypharmacy elderly, ICU, and diabetic patients

Always review patient’s medication list and consult with a pharmacist for complex situations.

Side Effects

Common Side Effects

• Local phlebitis, pain, redness, or swelling at injection site
• Hyperglycemia (overcorrection especially if diabetic)
• Fluid overload (with repeated dosing or in renal/cardiac impairment)
• Tissue necrosis with extravasation (vesicant)

Serious/Rare Side Effects

• Pulmonary edema in susceptible patients
• Thrombosis or embolism (from hyperosmolar solution)
• Electrolyte disturbances (esp. if repeated large doses)

If extravasation occurs: Stop infusion immediately and treat per protocol (possible hyaluronidase/local management required).

Warnings and Precautions

• Do not use if solution is discolored, cloudy, or contains particulates.
• Confirm IV line patency—extravasation can cause severe tissue necrosis and sloughing.
• Monitor serum glucose closely, especially in patients with diabetes, CNS disease, or altered renal/cardiac function.
• Caution in patients at risk for fluid overload, intracranial hemorrhage, or hyperosmolar syndromes.
• Not for IM or subcutaneous administration.
• Not intended for routine nutritional replacement.
• Pregnancy/lactation: Administer only if clearly necessary.